Completed PHASE2 INTERVENTIONAL 1-arm NCT02893111

Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

Sponsor: Tianjin Medical University General Hospital

Conditions Neuromyelitis Optica Spectrum Disorder

Interventions Bortezomib

Updated 8 times since 2017 Last updated: Apr 10, 2024 Started: Dec 31, 2015 Primary completion: Dec 25, 2016 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuromyelitis Optica Spectrum Disorder, this trial is completed. The trial is conducted by Tianjin Medical University General Hospital and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Oct 2018 — Nov 2018 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University General Hospital

Data source: Tianjin Medical University General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China